NEW YORK (GenomeWeb) – BG Medicine said on Wednesday that it has effected a one-for-four reverse stock split to remain listed on the Nasdaq.

The reverse split increases the share price of the company's stock above the minimum $1 bid price to continue listing on the Nasdaq Capital Market. The firm's shares opened at $1.61 per share today after closing at $.43 per share on Wednesday. In early morning trading, the stock rose to $2 per share.

The stock split reduced the number of BG Medicine's common shares outstanding to about 8.6 million shares from about 34.6 million shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.